Literature DB >> 10969823

ATP4- mediates closure of pancreatic beta-cell ATP-sensitive potassium channels by interaction with 1 of 4 identical sites.

E Markworth1, C Schwanstecher, M Schwanstecher.   

Abstract

In pancreatic beta-cells, cytosolic [ATP(4-)] critically controls insulin secretion via inhibition of ATP-sensitive potassium (KATP) channels. These channels are heteromultimers composed with a 4:4 stoichiometry of an inwardly rectifying K+ channel subunit (Kir6.2) plus a regulatory sulfonylurea receptor. To elucidate stoichiometry of ATP(4-) action, we analyzed ATP(4-) sensitivity of channels coassembled from wild-type Kir6.2 and a loss of ATP(4-) sensitivity mutant (G334D). Concentration-inhibition curves for cDNA ratios of 1:1 or 1:10 resembled those for channel block resulting from interaction with 1 of 4 sites, whereas models for inhibition requiring occupation of 2, 3, or 4 sites were incongruous. Random assembly of wild-type Kir6.2 with the G334D mutant was confirmed by controls, which assessed the effect of an additional mutation that induced strong rectification (N160D). We conclude 4 identical noncooperative ATP(4-) sites to be grouped within 1 KATP channel complex, with occupation of 1 site being sufficient to induce channel closure. This architecture might facilitate coupling of [ATP(4-)] to insulin secretion and may protect against diabetic dysregulation resulting from heterozygous mutations in Kir6.2.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10969823     DOI: 10.2337/diabetes.49.9.1413

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  24 in total

1.  ATP-dependent interaction of the cytosolic domains of the inwardly rectifying K+ channel Kir6.2 revealed by fluorescence resonance energy transfer.

Authors:  Takashi Tsuboi; Jonathan D Lippiat; Frances M Ashcroft; Guy A Rutter
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-17       Impact factor: 11.205

2.  Concerted gating mechanism underlying KATP channel inhibition by ATP.

Authors:  Peter Drain; Xuehui Geng; Lehong Li
Journal:  Biophys J       Date:  2004-04       Impact factor: 4.033

3.  Functional analysis of a structural model of the ATP-binding site of the KATP channel Kir6.2 subunit.

Authors:  Jennifer F Antcliff; Shozeb Haider; Peter Proks; Mark S P Sansom; Frances M Ashcroft
Journal:  EMBO J       Date:  2005-01-13       Impact factor: 11.598

Review 4.  ATP-sensitive potassium channelopathies: focus on insulin secretion.

Authors:  Frances M Ashcroft
Journal:  J Clin Invest       Date:  2005-08       Impact factor: 14.808

5.  Kir6.2 mutations causing neonatal diabetes provide new insights into Kir6.2-SUR1 interactions.

Authors:  Paolo Tammaro; Christophe Girard; Janne Molnes; Pål R Njølstad; Frances M Ashcroft
Journal:  EMBO J       Date:  2005-06-16       Impact factor: 11.598

6.  Incomplete dissociation of glibenclamide from wild-type and mutant pancreatic K ATP channels limits their recovery from inhibition.

Authors:  U Russ; P Kühner; R Prager; D Stephan; J Bryan; U Quast
Journal:  Br J Pharmacol       Date:  2009-01-13       Impact factor: 8.739

7.  A gating mutation at the internal mouth of the Kir6.2 pore is associated with DEND syndrome.

Authors:  Peter Proks; Christophe Girard; Shozeb Haider; Anna L Gloyn; Andrew T Hattersley; Mark S P Sansom; Frances M Ashcroft
Journal:  EMBO Rep       Date:  2005-05       Impact factor: 8.807

Review 8.  Current understanding of K ATP channels in neonatal diseases: focus on insulin secretion disorders.

Authors:  Yi Quan; Andrew Barszczyk; Zhong-ping Feng; Hong-shuo Sun
Journal:  Acta Pharmacol Sin       Date:  2011-05-23       Impact factor: 6.150

9.  Activation of the K(ATP) channel by Mg-nucleotide interaction with SUR1.

Authors:  Peter Proks; Heidi de Wet; Frances M Ashcroft
Journal:  J Gen Physiol       Date:  2010-10       Impact factor: 4.086

Review 10.  K(ATP) channelopathies in the pancreas.

Authors:  Maria S Remedi; Joseph C Koster
Journal:  Pflugers Arch       Date:  2009-11-18       Impact factor: 3.657

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.